Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.

Lattanzi, Simona; Trinka, Eugen; Striano, Pasquale; Zaccara, Gaetano; Del Giovane, Cinzia; Nardone, Raffaele; Silvestrini, Mauro; Brigo, Francesco (2020). Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis. Epilepsia, 61(6), pp. 1090-1098. Wiley-Blackwell 10.1111/epi.16546

Preview	Text Lattanzi Epilepsia 2020_AAM.pdf - Accepted Version Available under License Publisher holds Copyright. Download (569kB) | Preview
	Text Lattanzi Epilepsia 2020.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (825kB)

OBJECTIVE

To evaluate the potential impact of concomitant clobazam (CLB) use on the efficacy of cannabidiol (CBD) treatment in patients with Dravet syndrome and Lennox-Gastaut syndrome using meta-analytical techniques.

METHODS

We searched for randomized, placebo-controlled, single- or double-blinded trials. The proportion of patients who achieved ≥50% reduction from baseline in seizure frequency during the treatment period was assessed according to CLB status. Risk ratios (RRs) with 95% confidence intervals (CIs) were estimated.

RESULTS

Four trials were included and enrolled 714 participants, 429 for the add-on CBD group and 285 for the add-on placebo group. Among CBD-treated patients, 240 (55.9%) were taking concomitant CLB (CLB-On) and 189 (44.1%) were not taking concomitant CLB (CLB-Off); in placebo-treated patients, 158 (55.4%) were CLB-On and 127 (44.6%) CLB-Off. The percentages of patients who had at least 50% reduction in seizure frequency during the treatment period were 29.1% in the CBD arm and 15.7% in the placebo group among CLB-Off patients (RR = 1.80, 95% CI = 1.12-2.90, P = .015). Among CBL-On patients, the ≥50% reduction in seizure frequency was found in 52.9% and 27.8% in the CBD and placebo groups, respectively (RR = 1.85, 95% CI = 1.40-2.44, P < .001).

SIGNIFICANCE

CBD was associated with a higher rate of seizure response in comparison to placebo when added to the existing antiepileptic regimen both in patients taking and in those not taking concomitant CLB. The lack of randomization for CLB status and the limited sample size need to be considered in the interpretation of the findings.

Interest & Impact

Downloads

505 since deposited on 05 Jun 2020
129 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item